Company Overview
| Stock Name | Akeso |
|---|---|
| Stock Code | 09926 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 臨床階段生物製藥公司,致力於首創及同類最佳療法的自主發現、開發及商業化,專注於腫瘤、免疫及其他治療領域的未決醫療需求。 |
| Listing Date | 2020-04-24 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 廣東省中山市火炬開發區神農路6號 |
| Business Address (Hong Kong) | 香港 銅鑼灣 希慎道33號 利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | akesobio.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 16.18 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 16,180 |
| Par Value | To be extracted |
| Offer Period | 2020-04-14 to 2020-04-17 |
| Global Offering Shares | 159,500,000 shares |
| HK Public Offer Shares (Initial) | 15,950,000 shares (10.0%) |
| Public Offer Lots (Initial) | 15,950lots (Pool A7,975lots,Pool B7,975lots) |
| International Placing Shares (Initial) | 143,545,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 763,133,176 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 49.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,580,710,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 16,180 |
| 2 lots | 2,000 | HK$ 32,360 |
| 3 lots | 3,000 | HK$ 48,540 |
| 4 lots | 4,000 | HK$ 64,720 |
| 5 lots | 5,000 | HK$ 80,900 |
| 6 lots | 6,000 | HK$ 97,080 |
| 7 lots | 7,000 | HK$ 113,260 |
| 8 lots | 8,000 | HK$ 129,440 |
| 9 lots | 9,000 | HK$ 145,620 |
| 10 lots | 10,000 | HK$ 161,800 |
| 15 lots | 15,000 | HK$ 242,700 |
| 20 lots | 20,000 | HK$ 323,600 |
| 25 lots | 25,000 | HK$ 404,500 |
| 30 lots | 30,000 | HK$ 485,400 |
| 35 lots | 35,000 | HK$ 566,300 |
| 40 lots | 40,000 | HK$ 647,200 |
| 45 lots | 45,000 | HK$ 728,100 |
| 50 lots | 50,000 | HK$ 809,000 |
| 60 lots | 60,000 | HK$ 970,800 |
| 70 lots | 70,000 | HK$ 1,132,600 |
| 80 lots | 80,000 | HK$ 1,294,400 |
| 90 lots | 90,000 | HK$ 1,456,200 |
| 100 lots | 100,000 | HK$ 1,618,000 |
| 150 lots | 150,000 | HK$ 2,427,000 |
| 200 lots | 200,000 | HK$ 3,236,000 |
| 250 lots | 250,000 | HK$ 4,045,000 |
| 300 lots | 300,000 | HK$ 4,854,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 350 lots | 350,000 | HK$ 5,663,000 |
| 400 lots | 400,000 | HK$ 6,472,000 |
| 450 lots | 450,000 | HK$ 7,281,000 |
| 500 lots | 500,000 | HK$ 8,090,000 |
| 600 lots | 600,000 | HK$ 9,708,000 |
| 700 lots | 700,000 | HK$ 11,326,000 |
| 800 lots | 800,000 | HK$ 12,944,000 |
| 900 lots | 900,000 | HK$ 14,562,000 |
| 1,000 lots | 1,000,000 | HK$ 16,180,000 |
| 2,000 lots | 2,000,000 | HK$ 32,360,000 |
| 3,000 lots | 3,000,000 | HK$ 48,540,000 |
| 4,000 lots | 4,000,000 | HK$ 64,720,000 |
| 5,000 lots | 5,000,000 | HK$ 80,900,000 |
| 6,000 lots | 6,000,000 | HK$ 97,080,000 |
| 7,000 lots | 7,000,000 | HK$ 113,260,000 |
| 7,975 lots | 7,975,000 | HK$ 129,035,500 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 93.7B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 12,347,494,787 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币346.5百万元 |
| Period-End Cash Balance | 人民币1,186.0百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 2,826 | 70,879 |
| Cost of sales | 0 | 0 |
| Gross profit | 2,826 | 70,879 |
| Other income and gains, net | 27,045 | 50,186 |
| Administrative expenses | -20,157 | -55,421 |
| Operating profit | -151,708 | -340,718 |
| Net finance costs | -2,646 | -5,736 |
| Profit before tax | -154,354 | -346,454 |
| Income tax expense | 0 | 0 |
| Profit for the year | -154,354 | -346,454 |
| Profit attributable to owners | -142,307 | -335,386 |
Balance Sheet
| Item | 2018 | 2019 |
|---|---|---|
| Cash and cash equivalents | 313,716 | 1,186,044 |
| Inventories | 16,969 | 15,523 |
| Total current assets | 457,517 | 1,255,964 |
| Total assets | 651,718 | 1,672,939 |
| Total current liabilities | 86,236 | 119,761 |
| Total liabilities | 163,623 | 1,457,234 |
| Total equity | 488,095 | 215,705 |
| Equity attributable to owners | 441,216 | -6,353 |
| Interest-bearing borrowings | 58,560 | 211,375 |
Cash Flow Statement
| Item | 2018 | 2019 |
|---|---|---|
| Net cash from operating activities | -123,417 | -219,595 |
| Net cash from investing activities | -26,365 | -127,894 |
| Net cash from financing activities | 246,428 | 1,230,192 |
| Net increase in cash | 96,646 | 882,703 |
| Depreciation of PP&E | 10,443 | 13,419 |
| Depreciation of right-of-use assets | 2,482 | 2,964 |
| Amortisation of intangible assets | 46 | 109 |
| Purchase of PP&E | -72,698 | -136,273 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 24.3 |
|---|---|
| First Day Open | HK$ 23.5 |
| First Day Change | 50.19% |
| First Day Volume | 98779200.0 |
| First Day Turnover | 2372500000.0 |
| Use of Proceeds | 1、約75.0%,或1,827.7百萬港元,將主要用于以下產品研發及商業化;
2、約15.0%,或365.5百萬港元,將用于在中國廣州及中山發展生產及研發設施,其中大部分將用于購買新機器、儀器及設備以及擴展生產設施;
3、約10.0%,或243.7百萬港元,將用于我們的一般公司及營運資金用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (4)
Joint Bookrunners (7)
Morgan Stanley Asia Limited CE AAD291
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
交银国际证券有限公司 CE APJ121
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
BOCI ASIA LIMITED CE AET863
CMB International Capital Holdings Corporation Limited CE AJB801
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (7)
Morgan Stanley Asia Limited CE AAD291
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
交银国际证券有限公司 CE APJ121
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
BOCI ASIA LIMITED CE AET863
CMB International Capital Holdings Corporation Limited CE AJB801
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | AIHC Master Fund | 39,042,340 HKD | — | 1.51% | — | 6 months | 2020-10-24 |
| 2 | Boyu Capital Opportunities Master Fund | 78,084,680 HKD | — | 3.03% | — | 6 months | 2020-10-24 |
| 3 | CRF Investment Holdings Company Limited | 39,042,340 HKD | — | 1.51% | — | 6 months | 2020-10-24 |
| 4 | Fidelity International | 507,615,140 HKD | — | 19.67% | — | 6 months | 2020-10-24 |
| 5 | Hankang Biotech Fund I, L.P. | 23,428,640 HKD | — | 0.91% | — | 6 months | 2020-10-24 |
| 6 | Hudson Bay Master Fund LTD | 78,084,680 HKD | — | 3.03% | — | 6 months | 2020-10-24 |
| 7 | Lake Bleu Prime Healthcare Master Fund Limited | 351,429,600 HKD | — | 13.62% | — | 6 months | 2020-10-24 |
| 8 | OrbiMed Funds | 117,143,200 HKD | — | 4.54% | — | 6 months | 2020-10-24 |
| 9 | 中国国有企业结构调整基金股份有限公司 | 39,042,340 HKD | — | 1.51% | — | 6 months | 2020-10-24 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 夏瑜 | — |
| Company Secretary | 席曉捷、陳芃霏 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 夏瑜博士(约16.56%)、李百勇博士(约7.16%)、王忠民博士(约6.19%)、Waterband Limited(代表张鹏博士家族信托,约4.58%)为控股股东及主要股东。 |
|---|




